The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with early Alzheimer's disease, reversing its initial decision from four ...

According to a New York Times report this week, Eisai and Eli Lilly, in the clinical trials for their respective Alzheimer’s drugs Leqembi and Kisunla, genetically tested participants to ...